0001520262 2026-02-12 2026-02-12 true 0001520262 Alkermes plc. 8-K/A 2026-02-12 L2 001-35299 98-1007018 Connaught House 1 Burlington Road Dublin 4 IE D04 C5Y6 353 1-772-8000 false false false false Ordinary shares, $0.01 par value ALKS NASDAQ false On February 12, 2026, Alkermes plc (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”), reporting, among other items, that the Company completed the previously announced acquisition of the entire issued and outstanding ordinary share capital of Avadel Pharmaceuticals plc (“Avadel”) and Avadel became a wholly owned subsidiary of the Company (the “Acquisition”).  This Amendment No. 1 on Form 8-K/A (this “Form 8-K/A”) amends and supplements Item 9.01 of the Original Form 8-K to provide the financial statements and pro forma financial information required by Items 9.01(a) and (b) of Form 8-K. Such financial information was excluded from the Original Form 8-K in reliance on the instructions to such items. This Form 8-K/A does not amend any other item of the Original Form 8-K.